ClinicalTrials.gg
Drug

Rimegepant clinical trials

Also written BHV-3000 and Nurtec ODT.

studies test it
46
open now
20
in phase 3
19
first study started
2011

How each study uses rimegepant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the rimegepant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Feb 2020 · NURTEC ODT · NDA 212728 (FDA, Drugs@FDA)
European Union
25 Apr 2022 · Vydura · EMEA/H/C/005725 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Rimegepant
31
Rimegepant 75 mg ODT
3
Rimegepant 75 MG
3
Rimegepant 75mg Orally Disintegrating Tablets (ODT)
2

Brand

Nurtec ODT
2

Development codes

BHV-3000
10

Studies by the year they started

46 studies that test it; most in 2026 (12)

Studies that test rimegepant, by start year
YearStudies
20112
20173
20182
20191
20201
20214
202211
20231
20243
20256
202612

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
16
Phase 3
19
Phase 4
10
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 27 · Other 19

Pfizer (27) · Mayo Clinic (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2) · Antonios Likourezos (2) · Weill Medical College of Cornell University (1) · Chinese PLA General Hospital (1) · Shanghai Zhongshan Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Often tested with

Tested in the same studies.

Zavegepant (2) · Aspirin (1) · Ketamine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1) · Immune checkpoint inhibitors (1) · Rizatriptan (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test rimegepant, phase 3 first.

Studies

Open first, then newest update. How each study uses rimegepant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test rimegepant →

As the comparator · 2 — what is tested is compared with rimegepant

Codes

What other systems call rimegepant · ClinicalTrials.gg INT006230

  • MeSH (NLM) C578443rimegepant sulfateConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 997WVV895XRIMEGEPANTConfirmed FDA, Wikidata
  • RxNorm 2282307One source FDA
  • Wikidata Q27272184rimegepantConfirmed FDA, Wikidata
  • NCI Thesaurus C152220RimegepantOne source FDA
  • DrugBank DB12457One source Wikidata

Also registered as rimegepant sulfate (UNII 1383NM3Q0H · RxNorm 2282322).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.